Gefitinib (Iressa, ZD1839), an inhibitor of epidermal growth factor receptortyrosine kinase (EGFR-TK), has shown potent anti-tumor effects and improved symptom and quality-of-life of a subset of patients with advanced NSCLC.
INTRODUCTION
Lung cancer, the leading cause of cancer-death worldwide, is a major health problem in many countries. Chemotherapy is the mainstay for treatment of this disease; surgery is rarely indicated because by the time of diagnosis the majority of lung tumors have reached locally-advanced stage III (44%) or metastatic stage IV (32%) (1) . Nevertheless, a large meta-analysis revealed that platinum-based chemotherapy prolongs for only about 6 weeks the median survival time of patients with advanced non-small cell lung cancer (NSCLC), compared with the best supportive care (2) . Within the last decade a number of new cytotoxic agents such as paclitaxel, docetaxel, gemcitabine, and vinorelbine have emerged to offer multiple choices for patients with advanced lung cancer. However, each of those regimens confers only a modest survival benefit compared with cisplatin-based therapies (3, 4) . To overcome these limitations, new therapeutic strategies that rely on agents designed to target specific tumor-associated molecules are under development (5, 6) .
Gefitinib (Iressa, ZD1839) is an orally administered inhibitor of epidermal growth factor receptor-tyrosine kinase (EGFR-TK), an enzyme involved in certain signaling pathways that drive proliferation, invasion, and survival of cancer cells (7) . Gefitinib has shown potent anti-tumor effects and brought about rapid improvements in NSCLC-related symptoms and quality of life among some patients with advanced NSCLC who had not responded to platinum-based chemotherapy. In a randomized, double-blind phase II monotherapy trial (the IDEAL 1 trial), the use of gefitinib as a 2nd or 3rd line of chemotherapy achieved tumor-response rates of 18.4% (95%CI: 11.0-25.9%) for advanced NSCLCs; in the IDEAL 2 trial, this drug as the 3rd or 4th line of chemotherapy achieved 11.8% (95%CI: 6.2-19.7%) tumor response (8) (9) (10) .
Moreover, in these trials the drug achieved high rates of disease-control (54.4% in IDEAL 1, 42.2% in IDEAL 2) and of overall improvement in symptoms (40.3% in IDEAL 1, 43.1% in IDEAL 2). The results were promising when compared with responses to conventional cytotoxic agents, but about half of the patients enrolled in these studies showed no improvement in symptoms and in some cases the medication caused serious adverse effects, including life threatening ones such as interstitial pneumonia (11) . The figures do indicate considerable 4 potential for improving prognosis and quality of life for many patients with advanced NSCLC, if we could match treatments to individual cases by using this type of drug more effectively. One approach to that goal is to identify "cancer profiles" of individual NSCLCs and determine in advance which tumors are likely to respond to gefitinib.
In the study reported here, we applied a cDNA microarray system representing 27,648 genes to select a defined set of genes that could predict This protein was significantly up-regulated in non-responders, but was not expressed in responders.
5

RESULTS
Response to gefitinib treatment
Of the 53 patients enrolled in this trial, 46 had tumors diagnosed as adenocarcinomas (86.8%); five were squamous-cell carcinomas (9.4%); two were large cell carcinomas (3.8%). Fifteen patients achieved a PR and nobody revealed a CR; 17 patients were classified as SD, and 19 as PD. No clinicalresponse data were available for two of the patients. The tumor-response rate (CR+PR/CR+PR+SD+PD) for this treatment was 29.4%, and the disease control rate (CR+PR+SD/CR+PR+SD+PD) was 62.8% (Table 1) .
Tumor samples were collected from 43 patients. Samples from 32 of those 43 contained sufficient numbers of cancer cells for analysis of expression profiles on our cDNA microarray. The numbers of samples that were judged to be suitable for further microarray analysis, were 8 for PR, 7 for SD, and 13 for PD ( Table 2 and Fig. 1 ). 17 of the 28 samples were analyzed as learning cases (7 for PR and 10 for PD), and 11 were as test cases (1 for PR, 3 for PD, and 7 for SD) for establishing a predictive scoring system for the efficacy of gefitinib treatment. For further validation of the prediction system, another blinded set of samples from 5 newly enrolled test-cases (4 for PD and 1 for SD) were obtained and added finally to the initial 11 test cases above.
Expression of EGFR and AKT
To determine the status of EGFR and AKT, a downstream effector molecule of EGFR in tumor tissue samples for microarray analysis, we carried out immunohistochemical staining with anti-EGFR, anti-phospho EGFR (p-EGFR), anti-AKT, and anti-phospho AKT (p-AKT) antibodies. As shown in Tables 5C,   high levels of EGFR, p-EGFR, AKT, and p-AKT protein expression was detected in most NSCLC samples examined, but no correlation between any of these protein expression and sensitivity to gefitinib was observed (p=0.999, 0.622, 0.999, and 0.546, respectively; Fisher's exact test).
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tumors from seven patients in the PR group (defined as responders) and those from 10 patients in the PD group (defined as non-responders) by comparing expression levels of 27,648 genes. (Table 2 and 3) .
We carried out a random-permutation test to distinguish between the two subclasses defined by tumor response, and identified 51 genes whose permutational p-values were less than 0.001 (Table 4 ). Expression levels of 40 genes were higher, and those of the other 11 were lower, in the non-responders.
Establishment of a predictive scoring system for the efficacy of gefitinib treatment
Based on the expression profiles of the 51 genes selected above, we tried to establish a predictive scoring system for the efficacy of gefitinib treatment.
Prediction scores, termed gefitinib response score (GRS), were calculated according to procedures described previously (see Methods). To determine the number of candidates that provided the best separation of the two groups, we ranked the 51 genes on the basis of the significance of their permutational pvalues and calculated prediction scores by the leave-one-out test, in decrements of 1 starting from the bottom of the rank-ordered list (51, 50, 49, 48 etc.). We calculated a classification score (CS), a standard we had previously defined for evaluation of the ability to discriminate two classes, for each set of genes.
As shown in Figure 2A , we obtained different prediction scores when the number of discriminating genes was changed. We obtained the best CS, meaning the best separation of responders from non-responders, when we calculated the scores using only the 12 top-ranked genes in our candidate list.
Hierarchical clustering analyses using all 51 genes, or only the top 12, classified all 17 cases into one of two groups according to the response to gefitinib (Fig 2B) . The two groups were most clearly separated when we used the top 12 genes for cluster analysis. Finally, we established a numerical drugresponse-scoring algorithm that might be clinically applicable for predicting sensitivity of an individual NSCLC to gefitinib, on the basis of expression levels of the 12 selected genes.
To validate this prediction system we investigated 8 additional ("test") 7 NSCLC cases (1 for PR and 7 for PD) that were completely independent of the 17 "learning" cases used for establishing the system. We examined geneexpression profiles in each of those samples and then calculated GRS on the basis of the expression levels of the 12 discriminating genes. As shown in Figure 2C , scores obtained by the GRS system were concordant with the clinical responses to gefitinib in all eight "test" cases.
GRS values for patients with SD in tumor response
GRS values for the eight test-SD patients were calculated according to the predictive scoring system established above. Although the values were widely distributed from -83.0 (predicted as non-responder) to 61.6 (responder), the scores of patients who retained SD status throughout the observation period were likely to be higher than those of patients who had been judged as SD at a certain time-point of the study but showed progression of the disease within three or four months after the start of treatment (Fig. 2C) . Although the GRS system was established on the basis of gene-expression profiles that distinguished between patients with PR and patients with PD (without SD) in tumor response, these results suggested the possibility that the GRS may serve in classifying SD patients into groups according to their response to gefitinib.
Validation of GRS with semi-quantitative RT-PCR analysis
To confirm differential expression of the top 12 predictive genes between PR and PD cases, expression values derived from microarray data were correlated with values from semi-quantitative RT-PCR of RNAs from the same patients (5 PR and 7 PD) (Table 5A ; Fig. 3A ). Spearman rank correlations were positive for all of the 12 genes and significantly positive for seven of 12 genes.
Immunohistochemical validation of GRS
To validate differential expression of the predictive protein markers between PR and PD cases, we carried out immunohistochemical staining with five different antibodies for AREG, TGFA, ADAM9, CD9, and OSMR, all of which were known to be involved in the ligand-EGFRs signaling and whose permutational p-8 values were less than 0.01 (Supplementary Material - Table) . We first stained paired tumor tissue sections obtained by TBB and lymph-node biopsy from the same patients using these 5 antibodies. No intra-patient differences on protein expression of these five markers were observed in three different patients (Fig.   3B ). We also validated the microarray data with the five markers in 11 NSCLC samples (5 for PR and 6 for PD). The results were consistent with the microarray data (Table 5B ; Fig. 3C ).
Serum levels of TGFA
To further evaluate the availability of the prediction system in routine clinical situations, we detected TGFA protein which was known to be the ligand for EGFR and whose permutational p-values were less than 0.01, using ELISA in serum samples from 5 PR, 10 SD, and 20 PD patients that were independently collected for serological test and were not enrolled in microarray analysis. The serum levels of TGFA were 19.0 ± 2.8 pg/ml (mean±SE) in PD patients, 13.9 ± 1.9 pg/ml in SD patients, and 12.8 ± 1.4 pg/ml in PR patients (Fig. 4) . Twelve of 20 serum samples from PD patients were positive for TGFA and all samples from PR patients were negative, when 16.0 pg/ml was used as a cutoff.
In vitro gefitinib treatment and AREG-autocrine assay AREG, a ligand for EGFR and other ERBB members was significantly overexpressed in non-responders but not (or hardly) detectable in responders. To investigate whether AREG protein leads to resistance of NSCLCs to gefitinib therapy when it is secreted in an autocrine manner, we performed the following biological analyses. We initially identified expression of AREG mRNA in lungadenocarcinoma cell lines NCI-H358 and -H522, but not in PC-9, by means of RT-PCR experiments (Fig. 5A) . Next, we performed flow-cytometric analysis 72 hours after treatment of PC-9 cells with 1.0 µM of gefitinib, and found that gefitinib increased the percentages of nuclei in sub-G1 (24%) compared with cells with no treatment (6%) (data not shown). This result suggested that gefitinib might induce apoptosis in PC-9 cells.
We then analyzed the viability of PC-9 cells, which are gefitinib-sensitive and do not express AREG, after culture in serum-free medium or in serum-free, 9 conditioned medium obtained from NCI-H358 or -H522 cells grown in the presence or absence of 0.5 or 1.0 µM of gefitinib. As shown in Figure 5B , the viability of PC-9 cells incubated in the serum-free, conditioned medium containing gefitinib was greater than that of PC-9 cells grown in serum-free medium with the same concentrations of gefitinib.
To investigate whether AREG, secreted in an autocrine manner, inhibits apoptosis of NSCLC cells treated with gefitinib, we cultured PC-9 cells in serum-free medium containing recombinant AREG protein at final concentrations of 1-100 ng/ml, in the presence or absence of 1.0 µM gefitinib.
The viability of PC-9 cells incubated with both AREG and 1.0 µM gefitinib was increased in comparison to cells incubated with 1.0 µM gefitinib only, in an AREG-dose-dependent manner (Fig. 5C ). On the other hand, recombinant AREG alone had no effect on the viability of PC-9 cells (Fig. 5C ). This observation appeared to indicate that AREG inhibits the apoptosis induced by gefitinib, but does not in itself affect cell viability.
DISCUSSION
A large body of evidence supports the view that molecules in the EGFR autocrine pathway are involved in a number of processes important to cancer formation and progression, including cell proliferation, angiogenesis, and metastatic spread (5) . Therapeutic blockade of specific signaling, therefore, could be a promising strategy for cancer treatment. Gefitinib, a synthetic anilinoquinazoline, inhibits the tyrosine kinase activity of EGFR by competing with adenosine triphosphate for a binding site on the intracellular domain of the receptor (7). In phase II trials (IDEAL 1 and IDEAL 2), use of gefitinib as a 2nd-, 3rd-, or 4th-line monotherapy for advanced NSCLC achieved tumor-response rates of nearly 20% (8-10), which were superior to those achieved with conventional cytotoxic agents. Multivariate analysis of patients in the IDEAL 1 study suggested that the response rate in females might be higher than in males, and higher in patients with adenocarcinomas than in patients with squamous-cell carcinomas (odds ratios 2.7 and 3.5 respectively) (9) . Recent study suggested that individuals in whom gefitinib is efficacious are more likely to have adenocarcinomas of the bronchioloalveolar subtype and to be never Table) . This result independently confirms no correlation between sensitivity to gefitinib and activation of AKT/STAT signaling. Therefore novel methods to precisely discriminate responders from non-responders in advance could allow a more focused use of gefitinib in clinical settings.
By statistical analysis of gene-expression profiles of advanced NSCLCs obtained on cDNA microarrays, we identified dozens of genes associated with sensitivity to gefitinib. We introduced a prediction-scoring system based on expression of the 12 genes that had shown the most significant differences in expression levels between responder (PR) and non-responder (PD) groups.
This set of genes was selected from expression profiles of lung adenocarcinomas; however, the GRS system successfully classified all eight of our "test" PR and PD cases in accord with their clinical responses to gefitinib, and one of them was a squamous-cell carcinoma. Moreover, this system was likely to separate intermediate tumor responses (SD) into two groups, one representing patients who succeeded in maintaining the tumor-static effect for a long period and the other representing patients who failed to do so, although validation of the system in larger prospective trial is warranted.
In practical terms, we need to predict the chemosensitivity of individual tumors using the minimally invasive techniques available at every hospital, because patients with advanced NSCLCs are rarely candidates for surgical resection of their tumors. Therefore we have tried to establish a prediction system that requires only the amount of cancerous tissue that can be obtained by, for example, flexible bronchofiberscopy. By verifying individual steps of the method, we were able to precisely profile gene expression in biopsy specimens as small as 1 mm. Relevant microarray results were confirmed by semiquantitative RT-PCR for 12 genes that showed the most significant differences to establish a GRS system. Furthermore, we validated the effectiveness of antibodies for 5 different biomarkers (AREG, TGFA, ADAM9, CD9, and OSMR), all of which were reported to be involved in the ligand-EGFR signaling, for discriminating potential responders from non-responders, in both TBB and lymph-node biopsy samples. These five markers are cell-surface or secretory proteins and should have significant advantages for development of a novel serum maker for predicting response to gefitinib treatment, because they are presented either on the cell surface or within the extracellular space, and/or in serum, making them easily accessible as molecular markers. In fact, we were able to detect serum TGFA proteins in lung-ADC patients by ELISA. Further evaluation of these markers for clinical use are necessary, however, the limited number of genes required for prediction should eventually enable laboratories to diagnose in advance the efficacy of gefitinib treatment for an NSCLC patient, using routine procedures such as serological examinations of blood, PCR experiments, or immunohistochemical analysis of biopsy specimens.
To our knowledge, this is the first report about gene-expression profiles of unresectable "advanced" lung cancers, although profiles of surgically resected specimens of "early" lung cancers have been reported (17, 18) .
However, about 70% of tumors in patients diagnosed with NCSLC are already locally advanced or metastatic, which generally renders them resistant to conventional therapeutic modalities. Therefore the genes listed here should be useful for disclosing molecular mechanisms of lung-cancer progression and 12 may be potential targets for drug development.
Gefitinib was developed as a "selective" inhibitor of EGFR-TK; however, no clear association between the level of EGFR activation and response to gefitinib has been found in vitro or in vivo (7, 19) . In clinical trials, gefitinib has been more effective against adenocarcinomas than against squamous-cell carcinomas (9,10), although over-expression of EGFR is less frequent in adenocarcinomas (20) . Therefore, it is important to identify which individual tumors are good targets for this treatment. In our analysis using clinical samples, the difference in EGFR (p-EGFR)/AKT (p-AKT) protein expression and EGFR mutation between treatment-sensitive patients and resistant patients were not significant. On the other hand, amphiregulin (AREG) and transforming growth factor alpha (TGFA), both of which encode the ligand for EGFR and other ERBB members, were significantly over-expressed in non-responders but not (or hardly) detectable in responders (p=0.0000000000093 and 0.0095 respectively; Table 4 ). The results of this trial support further evaluation of the GRS system in another set of study population with NSCLC patients treated with gefitinib. The prospective trial to evaluate the reliability of several prediction systems including our GRS and controversial tests for EGFR signaling status is in progress in our institute.
The significance of the ligands and the EGFR autocrine loop in growth and survival of lung-cancer cells is indisputable (20) (21) (22) , but the role of AREG in formation and progression of cancers is poorly understood. However, several lines of evidence suggest that over-expression of AREG is associated with shortened survival of patients with NSCLC (20) . Moreover, anti-apoptotic activity of AREG in human lung-adenocarcinoma cells was reported recently (21) . To investigate whether the anti-apoptotic activity of AREG leads to resistance of NSCLC cells to gefitinib therapy, we performed a biological assay using a gefitinib-sensitive but AREG-non-expressing NSCLC cell line, PC-9. We found that the anti-tumor activity of gefitinib on PC-9 cells was dramatically decreased by autocrine secretion of AREG. This evidence strongly suggests that although growth-factor signaling by the EGFR is markedly complicated at every step because of the multiplicity of ligands, dimerization partners, effectors, and downstream pathways (22) , AREG might be a principal activator of the (23), and ADAM9 is involved in activation of EGFR signaling by shedding the ectodomain of proHB-EGF (pro Heparin-binding epidermal growth factor-like growth factor) (24) . CD9 physically interacts with transmembrane TGFA. CD9 expression strongly decreases the growth factorand PMA-induced proteolytic conversions of transmembrane to soluble TGFA and strongly enhances the TGFA-induced EGFR activation (25) . OSMR is reported to be constitutively associated with ERBB2 in breast cancer cells (26) .
Although other target molecules for gefitinib have been suggested, our results suggest that EGFR signaling containing these components is at least one of the important processes involved in response to this drug.
Since gefitinib can induce apoptosis of some cancer cells in vivo, other molecules with anti-apoptotic activity, as well as AREG, may contribute to a tumor's resistance to the drug. AVEN (apoptosis, caspase-activation inhibitor), which was specifically expressed in our non-responders (p=0.00000000042), is known to enhance the anti-apoptotic activity of Bcl-xL and to suppress Apaf-1-mediated caspase activation (27). On the other hand, mechanisms regulating drug transport should also affect drug resistance. GCLC (glutamate-cysteine ligase, catalytic subunit), which plays an important role in cellular detoxification of anticancer drugs such as cisplatin, etoposide and doxorubicin (28), was overexpressed in our group of non-responders (p=0.00000012). As these genes correlated negatively with responses to chemotherapy in our panel of tumors (i.e. the higher the expression of these genes, the greater the resistance to gefitinib), they might be involved in the mechanism(s) leading to that resistance.
It should be noted also that the functions of nearly half of our candidate prediction-genes are unknown. Therefore further investigations will be needed 14 to reveal more clearly the biological events underlying responses of NSCLCs to gefitinib.
CONCLUSION
We identified 51 genes whose expression differed significantly between responders and non-responders to gefitinib among human lung carcinomas, and established a numerical scoring system, based on expression patterns of 12 of those genes, to predict the response of individual tumors to this drug.
Although further validation using a larger set of clinical cases will be necessary, the data presented here may yield valuable insights into the molecular events underlying signal-suppressing strategies and provide important information about gefitinib treatment for individual NSCLC patients by testing a set of genes with high predictive values. At the end of 4-month treatment (or withdrawal), the best overall response was evaluated for each patient based on definitions as follows: CR, patients who qualified for CR at two sequential examination points with an interval of at least 28 days between them; PR, patients judged as PR or better at two sequential examination points with an interval of at least 28 days between them; SD, patients who were SD or better at two sequential examination points at least 28 days apart but who did not qualify as CR or PR.
MATERIALS AND METHODS
Patients and tissue samples
The first judgment of an SD case must be done at or after the first tumor assessment point (28 days after randomization); PD, the patients determined as PD at or before the first tumor assessment point (28 days after randomization); Unknown, the patient does not qualify for a best response of increased disease, and all objective statuses after baseline (before randomization) and before progression are unknown.
Prior to the gefitinib treatment, tumor specimens were taken by trans- 
Microdissection
In view of significant differences in the proportions of cancer cells and various types of parenchymal cells that are present from one tumor to another, microdissection is a necessary means of obtaining precise gene-expression profiles on cDNA microarrays. Therefore we stained 8 µm-thick frozen sections with hematoxylin and eosin and collected cancer cells selectively, using the µCUT laser-microbeam microdissection system (Molecular Machines & Industries AG, Glattbrugg, Switzerland) (31). In this system tissue sections are mounted on a thin supporting polyethylene membrane that will be cut together with the target tissue; a pulsed-ultraviolet (UV) narrow-beam-focus laser cuts out cancer cells along a pre-selected track that can be observed on a video screen. The material to be extracted is never directly exposed to the laser but only circumscribed by it; unlike other LMM systems, this one allows recovery of dissected cells to proceed without radiation. Moreover, the membrane protects the tissue on the slide against cross-contamination. Using this system we were able to isolate small areas of tissue rapidly, and to isolate single cells from histological sections (Fig. 1) .
RNA extraction and T7-based RNA amplification
Total RNA was extracted from individual microdissected populations of cancer 
cDNA microarray
Our "genome-wide" cDNA microarray system contains 27,648 cDNAs selected from the UniGene database of the National Center for Biotechnology Information (32). Fabrication of the microarray, hybridization, washing, and detection of signal intensities were described previously (32). To normalize the amount of mRNA between tumors and controls, the Cy5/Cy3 ratio for each gene's expression was adjusted so that the averaged Cy5/Cy3 ratio of 52 housekeeping genes was equal to one. We assigned a cutoff value to each microarray slide using analysis of variance, and the Cy5/Cy3 ratio of the gene was calculated as follows: (1) if Cy5 (cancer sample) was lower than the cut off level, then the Cy5/Cy3 ratio of the gene was substituted by 2.5 percentile among the Cy5/Cy3 ratios of other genes whose Cy5 and Cy3 were higher than the cut off level; (2) if Cy3 (control sample) was lower than the cut off level, then the Cy5/Cy3 ratio of the gene was substituted by 97.5 percentile among the Cy5/Cy3 ratios of other genes whose Cy5 and Cy3 were higher than the cut off level; (3) if both Cy5 and Cy3 were lower than the cut off level, then the Cy5/Cy3 ratio of the gene was left blank.
Extraction of genes for predicting responsiveness to gefitinib
To discover genes that might be associated with sensitivity to gefitinib, individual measurements of about 27,648 genes were compared between the two groups of patients, one classified as responders to gefitinib (PR) and the other as non-responders (PD). To reduce the dimensionality of the number of potent genes that could discriminate between the two classes, we extracted only genes that fulfilled two criteria: 1) signal intensities were higher than the cut-off level in at least 60% of either group, and 2) | MED PR -MED PD | 1, where MED indicates the median calculated from log-transformed relative expression ratios in each group. Then random-permutation tests were applied to estimate the ability of individual genes to distinguish between the two classes (PR and PD); mean (µ) and standard deviations (σ) were calculated from the logtransformed relative expression ratios of each gene in both groups. A discrimination score (DS) for each gene was defined as follows:
. The samples were randomly permutated 10,000 times for each pair of groups.
Since the DS dataset of each gene showed a normal distribution, we calculated a p-value for the user-defined grouping.
Calculation of drug-response scores
We calculated gefitinib response scores (GRS) reflecting the expression levels of candidate prediction-genes according to procedures described previously We summed the votes to obtain total votes for responders (V PR ) and nonresponders (V PD ), and calculated GRS values as follows: GRS = ((V PR -V PD ) / (V PR + V PD )) X 100, where the GRS value reflects the margin of victory in the direction of either responder or non-responder. GRS values range from -100 to 100; the higher an absolute value of GRS, the stronger the prediction.
Cross-validation of scores and evaluation of the prediction system
at Pennsylvania State University on February 28, 2013 http://hmg.oxfordjournals.org/
Downloaded from
The prediction scores of all samples were obtained by a leave-one-out approach, in which one sample at a time was removed from the sample set; permutational p-values and mean values of the two classes were calculated for each gene using the remaining samples. The drug-response of the withheld sample was predicted by calculating the prediction score. These procedures were repeated for each sample (33,34).
To evaluate the reliability of the prediction system, we calculated a "classification score" (CS) using the GRS values of responders and nonresponders in each gene set, as follows: CS =(µ GRSpr -µ GRSpd )/(σ GRSpr + σ GRSpd ) (34).
A larger value of CS indicates better separation of the two groups by the prediction system.
Hierarchical clustering
We used web-available software ("Cluster" and "TreeView") written by M. Eisen (http://genome-www5.stanford.edu/MicroArray/SMD/restech.html) to create a graphic representation of the microarray data and to create a dendrogram of hierarchical clustering. Before the clustering algorithm was applied, the fluorescence ratio for each spot was first log-transformed and then the data for each sample were median-centered to remove experimental biases.
Semi-quantitative RT-PCR analysis
Aliquots (5.0 µg) of the same aRNA hybridized to the microarray slides from individual samples and from the normal control lung were reversely transcribed using oligo(dT) [12] [13] [14] [15] [16] [17] [18] 
Immunohistochemical analysis
To confirm the differential expression of AREG and transforming growth factoralpha (TGFA) proteins, both of which encode the ligand for EGFR and other ERBB members, and other 3 candidate markers (a disintegrin and metalloproteinase domain 9 (ADAM9), CD9 antigen (p24), and OSMR), which are also known to relate to the EGFR signaling, for predicting responders vs 
In vitro gefitinib treatment and AREG-autocrine assay
Human NSCLC (adenocarcinoma) cell lines PC-9, NCI-H358, and NCI-H522
were purchased from the American Type Culture Collection (ATCC; Rockville, MD, USA). To detect expression of AREG in these NSCLC cells, total RNA from 22 each line was reverse-transcribed for single-stranded cDNAs using oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and Superscript II (Invitrogen). Semi-quantitative reverse transcriptase-PCR (RT-PCR) was carried out as described previously (19) . 
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Immunohistochemical staining of representative samples from PD patients, using antibodies for other 4 prediction markers (TGFA, ADAM9, CD9, and OSMR) (X200). were shown as black bars: 19.0 ± 2.8 pg/ml (mean±SE) in PD patients, 13.9 ± 1.9 pg/ml in SD patients, and 12.8 ± 1.4 pg/ml in PR patients. 
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Effect of AREG on the viability of NSCLC cells in the absence of 1.0 µM gefitinib was also studied. Individual PC-9 cells were added to medium containing recombinant AREG protein but no gefitinib; 72 hours later, viability was measured by triplicate MTT assays (red bars). Cases that consented to the study (1) Learning cases were used for developing the GRS, whereas test cases were used for validation.
(2) Another blinded set of samples from 5 newly enrolled cases were also added to the tests later.
Best Overall Response 
